Phenotypes Associated with This Genotype

Genotype
MGI:5295756

• Allelic Composition: Rb1^tm3Tyj/Rb1^tm3Tyj; Rbl1^tm1Tyj/Rbl1^tm1Tyj; Rbl2^tm2.1Tyj/Rbl2^tm2.1Tyj
• Genetic Background: involves: 129S2/SvPas * 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased hepatocellular carcinoma incidence ( J:177573 )

• mice injected intrasplenicaly with adenovirus expressing Cre recombinase develop multiple liver lesions after a latency of 3-4 months

• tumors resemble human hepatocellular carcinoma

• expansion of populations of stem/progenitor cells suggests that these cells, not hepatocytes, are the initiating populations in hepatocellular carcinoma development

• mutants treated with DAPT, a gamma-secretase inhibitor, 75 days after adenoviral Cre injection, show macroscopically visible tumors 12 days after the beginning of treatment

liver/biliary system

increased hepatocellular carcinoma incidence ( J:177573 )

• mice injected intrasplenicaly with adenovirus expressing Cre recombinase develop multiple liver lesions after a latency of 3-4 months

• tumors resemble human hepatocellular carcinoma

• expansion of populations of stem/progenitor cells suggests that these cells, not hepatocytes, are the initiating populations in hepatocellular carcinoma development

• mutants treated with DAPT, a gamma-secretase inhibitor, 75 days after adenoviral Cre injection, show macroscopically visible tumors 12 days after the beginning of treatment

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
hepatocellular carcinoma		DOID:684	OMIM:114550	J:177573